Last reviewed · How we verify
NCT05914662: ZBR
Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM
Phase 2 trial testing Zanubrutinib, Bendamustine and Rituximab in Waldenstrom Macroglobulinemia in 42 participants. Currently enrolling.
15 March 2025
Quick facts
| Lead sponsor | Institute of Hematology & Blood Diseases Hospital, China |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 42 |
| Start date | 15 February 2023 |
| Primary completion | 15 March 2025 |
| Estimated completion | 15 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Zanubrutinib, Bendamustine and Rituximab — full drug profile →
Conditions studied
- Waldenstrom Macroglobulinemia — all drugs for Waldenstrom Macroglobulinemia →
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Who can join
18 and older, any sex, with Waldenstrom Macroglobulinemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the long-term efficacy of BTK inhibitor Zanubrutinib combined bendamustine and rituximab (ZBR) for time-limited treatment of Waldenstrom macroglobulinemia, The combination therapy is expected to improve the remission depth, prolong the remission time, and improve the progression-free survival and overall survival of newly diagnosed WM patients. On the one hand, the patients have to bear a long-term economic burden, which is often difficult for some patients to adhere to for a long time. On the other hand, in the course of long-term treatment of BTKi, drug resistance and intolerable side effects are prone to occur. At the same time, it can prevent the disease rebound after the withdrawal of BTKi, so as to achieve the phased withdrawal of WM
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Optimal use of BTK inhibitors in Waldenström's macroglobulinemia: combination or single drug approach?
Solia E, Kastritis E. · · 2024 · PMID 39734591 · DOI 10.1177/20406207241308771
Verify or expand the search:
- PubMed search for NCT05914662
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Waldenstrom Macroglobulinemia
Currently open trials in the same condition.
- NCT07231952 — A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacyti · Phase 2 · recruiting
- NCT06860880 — Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · NA · recruiting
- NCT06561347 — Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM · Phase 2 · recruiting
- NCT06510491 — Epcoritamab in Previously Treated WM · Phase 2 · recruiting
- NCT06151730 — Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies U · recruiting
Other Institute of Hematology & Blood Diseases Hospital, China trials
Trials by the same sponsor.
- NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
- NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
- NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
- NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
- NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05914662 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
- Last refreshed: 28 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05914662.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing